Ipca Laboratories Limited (IPCALAB.BO)
INR 1363.95
(4.85%)
INR 1363.95
(4.85%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 7.98 Billion INR | 14.62% |
| 2022 | 7.31 Billion INR | -30.37% |
| 2021 | 10.5 Billion INR | -19.75% |
| 2020 | 13.08 Billion INR | 85.16% |
| 2019 | 7.06 Billion INR | 39.8% |
| 2018 | 5.05 Billion INR | 95.45% |
| 2017 | 2.58 Billion INR | 15.75% |
| 2016 | 2.23 Billion INR | 40.16% |
| 2015 | 1.59 Billion INR | -58.84% |
| 2014 | 3.87 Billion INR | -40.6% |
| 2013 | 6.52 Billion INR | 35.26% |
| 2012 | 4.82 Billion INR | 19.91% |
| 2011 | 4.02 Billion INR | 21.82% |
| 2010 | 3.3 Billion INR | 8.19% |
| 2009 | 3.05 Billion INR | 103.08% |
| 2008 | 1.5 Billion INR | -23.22% |
| 2007 | 1.95 Billion INR | 10.67% |
| 2006 | 1.76 Billion INR | 101.44% |
| 2005 | 877.6 Million INR | -14.14% |
| 2004 | 1.02 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 2.93 Billion INR | 199.37% |
| 2023 Q2 | 2.7 Billion INR | 13.37% |
| 2023 Q1 | 2.38 Billion INR | 113.77% |
| 2023 FY | 8.38 Billion INR | 14.62% |
| 2023 Q3 | 2.54 Billion INR | -5.9% |
| 2023 Q4 | 981.5 Million INR | -61.4% |
| 2022 Q1 | 2.07 Billion INR | 31.02% |
| 2022 Q3 | 1.49 Billion INR | -24.18% |
| 2022 Q4 | 1.11 Billion INR | -25.31% |
| 2022 Q2 | 1.96 Billion INR | -5.12% |
| 2022 FY | 7.31 Billion INR | -30.37% |
| 2021 FY | 10.5 Billion INR | -19.75% |
| 2021 Q2 | 3.08 Billion INR | -14.43% |
| 2021 Q3 | 2.49 Billion INR | -19.27% |
| 2021 Q4 | 1.58 Billion INR | -36.43% |
| 2021 Q1 | 3.6 Billion INR | 104.45% |
| 2020 FY | 13.08 Billion INR | 85.16% |
| 2020 Q4 | 1.76 Billion INR | -46.35% |
| 2020 Q3 | 3.28 Billion INR | 1.63% |
| 2020 Q2 | 3.23 Billion INR | -41.0% |
| 2020 Q1 | 5.48 Billion INR | 318.91% |
| 2019 FY | 7.06 Billion INR | 39.8% |
| 2019 Q3 | 2.38 Billion INR | 3.82% |
| 2019 Q4 | 1.3 Billion INR | -45.11% |
| 2019 Q1 | 1.71 Billion INR | 33.91% |
| 2019 Q2 | 2.29 Billion INR | 34.01% |
| 2018 Q2 | 1.43 Billion INR | 65.25% |
| 2018 FY | 5.05 Billion INR | 95.45% |
| 2018 Q4 | 1.27 Billion INR | -36.54% |
| 2018 Q3 | 2.01 Billion INR | 40.99% |
| 2018 Q1 | 865.5 Million INR | 0.0% |
| 2017 FY | 2.58 Billion INR | 15.75% |
| 2016 FY | 2.23 Billion INR | 40.16% |
| 2015 FY | 1.59 Billion INR | -58.84% |
| 2014 FY | 3.87 Billion INR | -40.6% |
| 2013 FY | 6.52 Billion INR | 35.26% |
| 2012 FY | 4.82 Billion INR | 19.91% |
| 2011 FY | 4.02 Billion INR | 21.82% |
| 2010 FY | 3.3 Billion INR | 8.19% |
| 2009 FY | 3.05 Billion INR | 103.08% |
| 2008 FY | 1.5 Billion INR | -23.22% |
| 2007 FY | 1.95 Billion INR | 10.67% |
| 2006 FY | 1.76 Billion INR | 101.44% |
| 2005 FY | 877.6 Million INR | -14.14% |
| 2004 FY | 1.02 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | -38.598% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 81.09% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 11.121% |
| Granules India Limited | 6.81 Billion INR | -17.074% |
| Indoco Remedies Limited | 1.29 Billion INR | -517.431% |
| Achyut Healthcare Limited | 4.43 Million INR | -179724.245% |
| Ajanta Pharma Limited | 19.67 Billion INR | 59.443% |
| Alkem Laboratories Limited | 19.46 Billion INR | 58.994% |
| Alpa Laboratories Limited | 184.49 Million INR | -4225.599% |
| Brooks Laboratories Limited | 14.44 Million INR | -55167.313% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -364.664% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -548.302% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 88.217% |
| Eris Lifesciences Limited | 5.18 Billion INR | -54.014% |
| FDC Limited | 2.98 Billion INR | -167.248% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | -22.734% |
| Gufic Biosciences Limited | 1.32 Billion INR | -500.086% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | -80.534% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -1470.582% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 5351.88% |
| Lasa Supergenerics Limited | -458 Million INR | 1842.47% |
| Laurus Labs Limited | 3.94 Billion INR | -102.112% |
| Lupin Limited | 28.04 Billion INR | 71.543% |
| Mankind Pharma Limited | 21.51 Billion INR | 62.912% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -7856.73% |
| Megasoft Limited | -121.1 Million INR | 6689.873% |
| NATCO Pharma Limited | 25.96 Billion INR | 69.26% |
| Piramal Pharma Limited | 4.55 Billion INR | -75.132% |
| RPG Life Sciences Limited | 2.29 Billion INR | -248.148% |
| Sigachi Industries Limited | 1.47 Billion INR | -441.463% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 92.349% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -73.204% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -3101.833% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -1300.803% |
| Windlas Biotech Limited | 1.29 Billion INR | -514.417% |
| ZIM Laboratories Limited | 253.82 Million INR | -3044.085% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 81.487% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 293.937% |
| Divi's Laboratories Limited | 33.08 Billion INR | 75.875% |
| Hester Biosciences Limited | 364.81 Million INR | -2087.605% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -186.454% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -1644.226% |
| Bal Pharma Limited | 233.9 Million INR | -3311.84% |
| Strides Pharma Science Limited | 5.22 Billion INR | -52.715% |
| Venus Remedies Limited | 534.65 Million INR | -1392.675% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -155.125% |
| Nectar Lifesciences Limited | 923.8 Million INR | -763.883% |
| Shilpa Medicare Limited | 1.36 Billion INR | -484.115% |
| Aarti Drugs Limited | 7.14 Billion INR | -11.637% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -399.787% |
| Suven Life Sciences Limited | -1.22 Billion INR | 751.041% |
| Ind-Swift Limited | 1.22 Billion INR | -550.965% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 44.124% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 307.132% |
| Themis Medicare Limited | 392.58 Million INR | -1932.813% |
| Hikal Limited | 32.11 Million INR | -24753.94% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 68.5% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -1173.839% |
| Wockhardt Limited | -670 Million INR | 1291.134% |
| Jubilant Pharmova Limited | 5.18 Billion INR | -53.798% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -87901.588% |
| Neuland Laboratories Limited | 5.31 Billion INR | -50.065% |
| Morepen Laboratories Limited | 4.17 Billion INR | -91.206% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -3735.905% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -28964.753% |